cetrorelix has been researched along with Atrophy* in 1 studies
1 other study(ies) available for cetrorelix and Atrophy
Article | Year |
---|---|
Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia.
In the present study, we investigated the roles of TGF-β signaling pathway in a rat benign prostatic hyperplasia (BPH) model treated with cetrorelix. TGF-β1 and c-Myc expression were measured by qRT-PCR and Western blotting in the proximal and distal region of ventral prostatic lobes, respectively. We observed that treatment with cetrorelix led to a significant reduction of ventral prostate weight in a dose-dependent manner. In the proximal region, after cetrorelix treatment, the expression of TGF-β1 was dramatically increased (P<0.05), while the expression of c-Myc was significantly decreased (P<0.05). In comparison with the control group, the cetrorelix groups had more TUNEL-positive cells. Our findings strongly suggest that the TGF-β signaling pathway may be one of the major causes responsible for prostate volume reduction in BPH rats after cetrorelix treatment. Topics: Animals; Atrophy; Disease Models, Animal; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Male; Organ Size; Prostatic Hyperplasia; Proto-Oncogene Proteins c-myc; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1 | 2012 |